newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights

– Two Phase 2 clinical trials underway to evaluate MGTA-145 plus plerixafor; initial mobilization, collection, engraftment and disease outcome data in Multiple Myeloma patients to be first presented at the American Society of Clinical Oncology (ASCO)